Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard R Winkelmann

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Clinical Chemistry|June 19, 2007
Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study)Karl Winkler, Michael M Hoffmann, Bernhard R Winkelmann, et al.
Clinical Laboratory|October 28, 2011
Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study)Marcus E Kleber, Robert L Wolfert, Graciela Delgado De Moissl, et al.
Atherosclerosis|October 20, 2009
Association of the single nucleotide polymorphism rs599839 in the vicinity of the sortilin 1 gene with LDL and triglyceride metabolism, coronary heart disease and myocardial infarction. The Ludwigshafen Risk and Cardiovascular Health StudyMarcus E Kleber, Wilfried Renner, Tanja B Grammer, et al.
Diabetes|July 25, 2008
Lymphocytes of type 2 diabetic women carry a high load of stable chromosomal aberrations: a novel risk factor for disease-related early deathBernhard O Boehm, Peter Möller, Josef Högel, et al.
Circulation|January 13, 2010
Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health studyAndreas Ritsch, Hubert Scharnagl, Philipp Eller, et al.
Circulation|August 25, 2010
Homoarginine, cardiovascular risk, and mortalityWinfried März, Andreas Meinitzer, Christiane Drechsler, et al.
Diabetes/Metabolism Research and Reviews|March 9, 2011
Association of TCF7L2 SNPs with age at onset of type 2 diabetes and proinsulin/insulin ratio but not with glucagon-like peptide 1Guenther Silbernagel, Wilfried Renner, Tanja B Grammer, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 25, 2003
The variable number of tandem repeat polymorphism in the P-selectin glycoprotein ligand-1 gene is not associated with coronary heart diseasePeter Bugert, Michael M Hoffmann, Bernhard R Winkelmann, et al.
International Journal of Cardiology|April 22, 2014
Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC studyHubert Scharnagl, Marcus E Kleber, Bernd Genser, et al.
Clinical Pharmacology in Drug Development|November 20, 2018
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 TrialHans-Dirk Düngen, Lars Kober, Savina Nodari, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Clinical Chemistry|June 19, 2007
Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study)Karl Winkler, Michael M Hoffmann, Bernhard R Winkelmann, et al.
Clinical Laboratory|October 28, 2011
Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study)Marcus E Kleber, Robert L Wolfert, Graciela Delgado De Moissl, et al.
Atherosclerosis|October 20, 2009
Association of the single nucleotide polymorphism rs599839 in the vicinity of the sortilin 1 gene with LDL and triglyceride metabolism, coronary heart disease and myocardial infarction. The Ludwigshafen Risk and Cardiovascular Health StudyMarcus E Kleber, Wilfried Renner, Tanja B Grammer, et al.
Diabetes|July 25, 2008
Lymphocytes of type 2 diabetic women carry a high load of stable chromosomal aberrations: a novel risk factor for disease-related early deathBernhard O Boehm, Peter Möller, Josef Högel, et al.
Circulation|January 13, 2010
Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health studyAndreas Ritsch, Hubert Scharnagl, Philipp Eller, et al.
Circulation|August 25, 2010
Homoarginine, cardiovascular risk, and mortalityWinfried März, Andreas Meinitzer, Christiane Drechsler, et al.
Diabetes/Metabolism Research and Reviews|March 9, 2011
Association of TCF7L2 SNPs with age at onset of type 2 diabetes and proinsulin/insulin ratio but not with glucagon-like peptide 1Guenther Silbernagel, Wilfried Renner, Tanja B Grammer, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 25, 2003
The variable number of tandem repeat polymorphism in the P-selectin glycoprotein ligand-1 gene is not associated with coronary heart diseasePeter Bugert, Michael M Hoffmann, Bernhard R Winkelmann, et al.
International Journal of Cardiology|April 22, 2014
Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC studyHubert Scharnagl, Marcus E Kleber, Bernd Genser, et al.
Clinical Pharmacology in Drug Development|November 20, 2018
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 TrialHans-Dirk Düngen, Lars Kober, Savina Nodari, et al.
Pageof 8